Genine Winslow, CEO and Founder of Chameleon Biosciences will be participating in a panel discussion at the upcoming CureDuchenne’s National “FUTURES” Conference. CureDuchenne’s National “FUTURES” Conference. We’re pleased to participate because preclinical studies indicate potential application of EVADER™ gene therapy vectors to help improve the lives of people affected by Duchenne Muscular Dystrophy.
Chameleon Biosciences, Inc. is a Berkeley, California-based next generation gene therapy company developing EVADERTM technology. Preclinical studies indicate that EVADER gene therapy vectors improve transgene expression efficiencies, are resistant to neutralizing antibodies (see paper), and result in lower anti-capsid antibody production. These findings indicate that EVADER could enable the treatment of patients with pre-existing immunity and potentially allow for repeat dosing of gene therapy products.